ResearcherUniversity of PisaNo recent work listed
Eleonora Rofi
Matched on OpenAlex author ID A5007609959. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers
Papers 4
- Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-p… Co-author DOI 10.1038/s41397-020-00203-7↗
- Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Co-author DOI 10.3390/cancers13153738↗
- The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Co-author DOI 10.2217/pgs-2018-0149↗
- Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08297-z↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marzia Del Re · 4 shared papers, 2017–2021 · strength 0.38
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. DOI 10.3390/cancers13153738↗
- Paper The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. DOI 10.2217/pgs-2018-0149↗
- Caterina Vivaldi · 4 shared papers, 2017–2021 · strength 0.38
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. DOI 10.3390/cancers13153738↗
- Paper The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. DOI 10.2217/pgs-2018-0149↗
- Lorenzo Fornaro · 4 shared papers, 2017–2021 · strength 0.38
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. DOI 10.3390/cancers13153738↗
- Paper The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. DOI 10.2217/pgs-2018-0149↗
- Romano Danesi · 4 shared papers, 2017–2021 · strength 0.38
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. DOI 10.3390/cancers13153738↗
- Paper The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. DOI 10.2217/pgs-2018-0149↗
- Enrico Vasile · 4 shared papers, 2017–2021 · strength 0.38
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. DOI 10.3390/cancers13153738↗
- Paper The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. DOI 10.2217/pgs-2018-0149↗
- Silvia Catanese · 2 shared papers, 2021 · strength 0.23
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. DOI 10.3390/cancers13153738↗
- Irene Pecora · 1 shared paper, 2021 · strength 0.11
- Niccola Funel · 1 shared paper, 2019 · strength 0.09
- Chiara Caparello · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.